Search results: Sage Journals

Restricted accessResearch articleFirst published April, 2026

FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience

Jose Tinajero, Dat Ngo, Brian Lee [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2022

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

Silvia Park, Daehun Kwag, Tong Yoon Kim [...]

Therapeutic Advances in Hematology

Restricted accessResearch articleFirst published May, 2020

Combination Therapy May Reverse Venetoclax Resistance in Relapsed or Refractory AML

Dale L. Ludwig, Eileen M. Geoghegan

Genetic Engineering & Biotechnology News

Free accessResearch articleFirst published November, 2018

Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens

Wenfeng Luo, Huilan Yu, Xingli Zou [...]

Cancer Biomarkers

Free accessResearch articleFirst published February, 2022

Upregulated mitosis-associated genes CENPE,CENPF,and DLGAP5 predict poor prognosis and chemotherapy resistance of Acute Myeloid Leukemia

Mingyue Shi, Honggang Guo, Yanliang Bai [...]

Cancer Biomarkers

Open accessCase reportFirst published 2021

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia

Nerea Báez-Gutiérrez, Héctor Rodríguez-Ramallo, María Antonia-Pérez Moreno [...]

Therapeutic Advances in Hematology

Restricted accessCase reportFirst published August, 2019

Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases

Juan Antonio Flores-Jiménez, Michael Ariel Pimentel-Morales, Oscar González-Ramella [...]

Journal of Adolescent and Young Adult Oncology

Free accessReview articleFirst published June, 2017

Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape

Valeriy Sedov, Robert K. Stuart

Therapeutic Advances in Hematology

Open accessResearch articleFirst published 2023

Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia

Uday Kulkarni, Arun Kumar Arunachalam, Hamenth Kumar Palani [...]

Cell Transplantation

Restricted accessReview articleFirst published December, 2018

New and emerging therapies for acute myeloid leukaemia

Julian R Davis, David J Benjamin, Brian A Jonas

Journal of Investigative Medicine

Restricted accessResearch articleFirst published April, 2026

FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience

Jose Tinajero, Dat Ngo, Brian Lee [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2022

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

Silvia Park, Daehun Kwag, Tong Yoon Kim [...]

Therapeutic Advances in Hematology

Restricted accessResearch articleFirst published May, 2020

Combination Therapy May Reverse Venetoclax Resistance in Relapsed or Refractory AML

Dale L. Ludwig, Eileen M. Geoghegan

Genetic Engineering & Biotechnology News

Free accessResearch articleFirst published November, 2018

Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens

Wenfeng Luo, Huilan Yu, Xingli Zou [...]

Cancer Biomarkers

Free accessResearch articleFirst published February, 2022

Upregulated mitosis-associated genes CENPE,CENPF,and DLGAP5 predict poor prognosis and chemotherapy resistance of Acute Myeloid Leukemia

Mingyue Shi, Honggang Guo, Yanliang Bai [...]

Cancer Biomarkers

Open accessCase reportFirst published 2021

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia

Nerea Báez-Gutiérrez, Héctor Rodríguez-Ramallo, María Antonia-Pérez Moreno [...]

Therapeutic Advances in Hematology

Restricted accessCase reportFirst published August, 2019

Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases

Juan Antonio Flores-Jiménez, Michael Ariel Pimentel-Morales, Oscar González-Ramella [...]

Journal of Adolescent and Young Adult Oncology

Free accessReview articleFirst published June, 2017

Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape

Valeriy Sedov, Robert K. Stuart

Therapeutic Advances in Hematology

Open accessResearch articleFirst published 2023

Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia

Uday Kulkarni, Arun Kumar Arunachalam, Hamenth Kumar Palani [...]

Cell Transplantation

Restricted accessReview articleFirst published December, 2018

New and emerging therapies for acute myeloid leukaemia

Julian R Davis, David J Benjamin, Brian A Jonas

Journal of Investigative Medicine